Broker recommendations for CARA Therapeutics
The CARA Therapeutics, Inc. stock is rated at 1.125 (on a scale 1-3, where 1 is ‘strong buy‘ and 3 is ‘strong sell‘) from Thursday 28 May, 2020 by a total of 8 brokers. This means that the consensus of the 8 different brokers is leaning toward to buy/moderate buy.
Sell
0 (0%) Underweight
0 (0%) Hold
1 (12.5%) Overweight
0 (0%) Buy
7 (87.5%)
Price target by analysts
The 8 latest analyst estimates, per Saturday 1 August, 2020, show the following high, low and average price targets.
Target Average: 33.12 USD
Target High: 40 USD
Target Low: 19 USD
Debate on population versus land mass turn into 2022 politics
Monday, 27 July 2020, 23:00:00
The stalemate has stalled the passage of the County Allocation of Revenue (CARA) Bill 2020, which will allow counties to get funds.
— The Standard Digital
Cara Therapeutics Expands Board of Directors with Appointment of Susan Shiff, Ph.D., M.B.A.
Tuesday, 30 June 2020, 13:00:00
STAMFORD, Conn., June 30, 2020 (GLOBE NEWSWIRE) — Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and…
— GlobeNewswire
Cara Therapeutics to Present at the Jefferies Virtual Healthcare Conference
Wednesday, 27 May 2020, 22:01:00
STAMFORD, Conn., May 27, 2020 (GLOBE NEWSWIRE) — Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and…
— GlobeNewswire
Is Cara Therapeutics (CARA) Stock a Solid Choice Right Now?
Friday, 15 May 2020, 17:00:00
Cara Therapeutics (CARA) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
— Zacks Investment Research
Earnings Preview: Cara Therapeutics (CARA) Q1 Earnings Expected to Decline
Tuesday, 28 April 2020, 18:34:08
Cara (CARA) doesn’t possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
— Zacks Investment Research
